Chris Brown
Executive Director, Business Development Transaction @GSK
Signup · Get unlimited contacts
WORK HISTORY
Executive Director, Business Development Transaction @GSK
Transaction lead for innovation-driven transactions that align to company R&D strategyKey Deals:2026: GSK enters agreement to acquire 35Pharma Inc.2025: GSK acquires exclusive rights from Syndivia for antibody-drug conjugate in prostate cancer2024: GSK and Duality Biologics option agreement for a novel antibody-drug conjugate (DB-13••••24: GSK and Flagship Pioneering collaboration to discover novel medicines and vaccines
EDUCATION
The Open University
MBA, Business Administration and Management, General
London Business School
Negotiating and Influencing Skills for Senior Managers
University of Southampton
Bachelor of Science - BS, Pharmacology
SKILLS
ABOUT CHRIS BROWN
Executive Director, Business Development Transaction at GSK
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.